Tumors frequently express unmutated self-tumor–associated antigens (self-TAAs). However,
trial results using self-TAAs as vaccine targets against cancer are mixed, often attributed to …

HLA molecules presenting peptides derived from tumor-associated self-antigens (self-TAA)
are attractive targets for T-cell–based immunotherapy of cancer. However, detection of such …

Identifying T-cell receptors (TCRs) that bind tumor-associated antigens (TAAs) with optimal
affinity is a key bottleneck in the development of adoptive T-cell therapy of cancer. TAAs are …

Targeting tumor-associated antigens (TAA) is a promising approach for cancer
immunotherapy. Targeting TAA has the potential to minimize the off-target toxicities of …

Cancers frequently evade immune-recognition by lowering peptide: MHC-I complexes on
their cell surface. Limited peptide supply due to TAP-deficiency results in such MHC-Ilow …

After a decade of cancer immunotherapy (both active and adoptive), based on the use of
well-defined tumor-associated antigens (TAA), and despite the large amount of new …

Tumor-associated antigens (TAAs) are monomorphic self-antigens that are proposed as
targets for immunotherapeutic approaches to treat malignancies. We investigated whether T …

Despite their origin from self-tissue, tumor cells can be immunogenic, triggering immune
responses that can profoundly influence tumor biology. The clinical implications are obvious …

A major goal of immunotherapy for cancer is the activation of T cell responses against tumor-
associated antigens (TAAs). One important strategy for improving antitumor immunity is …

Tumor cells frequently escape from CD8+ T cell recognition by abrogating MHC-I antigen
presentation. Deficiency in processing components, like the transporter associated with …